Literature DB >> 8125716

A clinicopathologic study of in vitro sensitivity testing and Acanthamoeba keratitis.

M J Elder1, S Kilvington, J K Dart.   

Abstract

PURPOSE: To examine the extent of any correlation between the in vitro sensitivity and the clinical outcomes of Acanthamoeba keratitis.
METHODS: The clinical outcomes were correlated with the in vitro sensitivity of 23 isolates of 23 patients with culture-positive Acanthamoeba keratitis. The laboratory assay assessed the amoebicidal and cysticidal efficacy of 13 drugs.
RESULTS: Most agents were effective against the trophozoites in vivo. Polyhexamethylene biguanide (PHMB) and chlorhexidine were the most successful cysticidal agents, followed by sepazonium and propamidine. Clotrimazole, paramomycin, and ketoconazole were cysticidal in a few specimens, but usually in high concentrations. Neomycin was ineffective against cysts in vivo. Nineteen patients were treated with topical propamidine and neomycin, and a medical cure was obtained in nine (47%). There was poor correlation between the clinical outcomes of individual cases and the in vitro sensitivity testing. The medical failures were treated with topical PHMB and propamidine and eight of ten (80%) of these were medically cured. Two patients, however, were still culture positive after 28 and 41 weeks of treatment. PHMB has an excellent in vitro sensitivity profile, but the two cases of failure were sensitive to the drug and resistance had not developed.
CONCLUSIONS: In vitro sensitivity testing has been important in the screening of new agents, although disappointing in the management of individual cases in this set of studies.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8125716

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  36 in total

1.  Effect of combined chlorhexidine gluconate and neosporin on experimental keratitis with two pathogenic strains of Acanthamoeba.

Authors:  Zubeyde Akin Polat; Ayse Vural
Journal:  Parasitol Res       Date:  2011-12-09       Impact factor: 2.289

2.  Determination of amoebicidal activities of multipurpose contact lens solutions by using a most probable number enumeration technique.

Authors:  Tara K Beattie; David V Seal; Alan Tomlinson; Angus K McFadyen; Anthony M Grimason
Journal:  J Clin Microbiol       Date:  2003-07       Impact factor: 5.948

3.  Acanthamoeba keratitis: risk factors and outcome.

Authors:  J Hay; D V Seal
Journal:  Br J Ophthalmol       Date:  1996-08       Impact factor: 4.638

4.  Acanthamoeba keratitis: multicentre survey in England 1992-6. National Acanthamoeba Keratitis Study Group.

Authors:  C F Radford; O J Lehmann; J K Dart
Journal:  Br J Ophthalmol       Date:  1998-12       Impact factor: 4.638

5.  Evaluation of the activity of new cationic carbosilane dendrimers on trophozoites and cysts of Acanthamoeba polyphaga.

Authors:  Irene Heredero-Bermejo; Jose Luis Copa-Patiño; Juan Soliveri; Elena Fuentes-Paniagua; Francisco Javier de la Mata; Rafael Gomez; Jorge Perez-Serrano
Journal:  Parasitol Res       Date:  2014-10-31       Impact factor: 2.289

6.  Cytotoxic effect of organic solvents and surfactant agents on Acanthamoeba castellanii cysts.

Authors:  Hayam Mohamed Ezz Eldin; Rania Mohamed Sarhan
Journal:  Parasitol Res       Date:  2014-03-18       Impact factor: 2.289

7.  [Acanthamoeba keratitis].

Authors:  N Szentmáry; L Daas; P Matoula; S Goebels; B Seitz
Journal:  Ophthalmologe       Date:  2013-12       Impact factor: 1.059

8.  Efficacy of commercial soft contact lens disinfectant solutions against Acanthamoeba.

Authors:  Takeshi Kobayashi; Lindsay Gibbon; Tsuyoshi Mito; Atsushi Shiraishi; Toshihiko Uno; Yuichi Ohashi
Journal:  Jpn J Ophthalmol       Date:  2011-07-12       Impact factor: 2.447

9.  Efficacy of miltefosine for topical treatment of Acanthamoeba keratitis in Syrian hamsters.

Authors:  Zubeyde Akın Polat; Andreas Obwaller; Ayse Vural; Julia Walochnik
Journal:  Parasitol Res       Date:  2011-07-07       Impact factor: 2.289

10.  Evaluation of the in vitro activity of commercially available moxifloxacin and voriconazole eye-drops against clinical strains of Acanthamoeba.

Authors:  C M Martín-Navarro; A López-Arencibia; F Arnalich-Montiel; B Valladares; J E Piñero; J Lorenzo-Morales
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2013-05-19       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.